Changes in absorption and bioavailability of drugs have been described after bariatric surgery, especially shortly after the procedure. When a significant drug-drug interaction also occurs, it is difficult to predict the final combined effect of the surgery and the interaction. In this article, we present a case report of a patient with chronic psychiatric poly-medication including carbamazepine, a strong cytochrome P450 3A4 (CYP3A4) inducer. Significant changes in serum drug concentrations were observed during the 6 months after the surgery, including increased levels of quetiapine and trazodone, that cannot be attributed to the post-surgical alteration of absorption from the gastrointestinal tract. The influence of fluctuating carbamazepine levels on concomitant medication seemed to outweigh the effect of reduced absorption after surgery. This report highlights the need for careful pre-surgical evaluation of the patient's pharmacotherapy and pre- and post-operative therapeutic drug monitoring to prevent destabilisation of chronic conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1136/ejhpharm-2024-004236DOI Listing

Publication Analysis

Top Keywords

bariatric surgery
8
surgery
5
pharmacotherapy carbamazepine-treated
4
carbamazepine-treated patient
4
patient bariatric
4
surgery complex
4
complex interplay
4
interplay altered
4
absorption
4
altered absorption
4

Similar Publications

[Experiences with a novel bariatric bypass procedure (SASI)].

Orv Hetil

January 2025

1 Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Rendelőintézet, Általános-Mellkassebészeti Osztály Szolnok Magyarország.

View Article and Find Full Text PDF

Background: Metabolic and Bariatric Surgery (MBS) is often difficult to access for the adolescent population. Eligibility criteria have been recently updated to attempt to remove barriers in accessing this care.

Objectives: Analyze recent trends in adolescent MBS in the context of these recent policy changes.

View Article and Find Full Text PDF

Risk assessment for esophageal cancer after bariatric surgery: a comparative cohort study between sleeve gastrectomy and gastric bypass.

Surg Obes Relat Dis

December 2024

Department of Digestive Surgery, Magellan Center, Bordeaux University Hospital Pessac, Bordeaux, France; BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Univ. Bordeaux, Bordeaux, France. Electronic address:

Background: The risk of esophageal cancer after bariatric surgery is a matter of debate.

Objective: This study aims to evaluate the risk of esophageal cancer following sleeve gastrectomy (SG) and gastric bypass (GB).

Methods: We extracted data from the national discharge database (Programme De Médicalisation des Systèmes d'Information) for patients who underwent bariatric surgery in France between 2007 and 2020.

View Article and Find Full Text PDF

A population based study of bariatric surgery in Illinois.

Surg Obes Relat Dis

December 2024

Northwestern Quality Improvement, Research and Education in Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois; Division of General Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Background: Utilization of metabolic and bariatric surgery has increased significantly over the last 2decades, yet barriers to access remain.

Objectives: This study aimed to 1) define rates of metabolic and bariatric surgery utilization for qualifying adults in Illinois and 2) describe patient characteristics associated with undergoing surgery at Illinois hospitals with low metabolic and bariatric surgery volume.

Setting: Metabolic and bariatric surgery at all nonfederal Illinois hospitals was included.

View Article and Find Full Text PDF

Background: Bariatric surgery is the most effective intervention for severe pediatric obesity, but a subset of youth experience suboptimal weight loss and/or recurrent weight gain. Early re-initiation of obesity pharmacotherapy postoperatively may improve outcomes, though this has not been evaluated in pediatric populations.

Methods: A retrospective cohort study at a tertiary care children's hospital evaluated the safety and efficacy of reintroducing obesity pharmacotherapy within six weeks after laparoscopic sleeve gastrectomy (LSG).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!